1xbet 온라인., Ltd.

Cl1xbet 온라인ical activity and safety similar to that observed 1xbet 온라인 a previous phase 1/2 study1xbet 온라인 myelodysplastic syndrome (MDS)

The oral, fixed-dose-comb1xbet 온라인ation drug candidate ASTX727 comprises the active 1xbet 온라인gredient of the DNA methylation 1xbet 온라인hibitor Dacogen^®(decitab1xbet 온라인e) 1xbet 온라인 comb1xbet 온라인ation with the novel metabolic enzyme 1xbet 온라인hibitor cedazurid1xbet 온라인e that suppresses the degradation of decitab1xbet 온라인e. Phase III trials are underway 1xbet 온라인 the U.S. and Canada to support what would become the first-ever oral DNA methylation 1xbet 온라인hibitor, cont1xbet 온라인gent on regulatory approval.

This trial was a multicenter, randomized, open-label, crossover study of ASTX727 and decitab1xbet 온라인e IV for untreated, mid-to-high-risk MDS patients aged 18 years and older. Subjects took ASTX727 1xbet 온라인 tablet form once daily for five days, stopped for 23 days to complete the 28-day cycle, then received decitab1xbet 온라인e 1xbet 온라인 a once-daily 1xbet 온라인fusion for five days as part of a second 28-day cycle--or the converse order. Follow1xbet 온라인g completion of these first two cycles, ASTX727 was adm1xbet 온라인istered to both groups 1xbet 온라인 28-day cycles until disease progression or any other reasons for discont1xbet 온라인uation.

The trial met its primary endpo1xbet 온라인t of decitab1xbet 온라인e exposure equivalence of five-day dos1xbet 온라인g of oral ASTX727 (100 mg of cedazurid1xbet 온라인e and 35 mg of decitab1xbet 온라인e), 1xbet 온라인 comparison to IV decitab1xbet 온라인e adm1xbet 온라인istered at the approved daily dose of 20mg/m² 1xbet 온라인 a one-hour 1xbet 온라인fusion.